Biotech Products Services and Research, Inc. (BPSR)
Wednesday’s Closing PPS: $0.162
Before you continue to read my full juicy profile on (BPSR) I want to remind you of how well my last pick from Tuesday’s 1/10/17 trading session did!
KDRH opened yesterday’s trading session at $0.0169 and SOARED to a high of $0.076 for real intra-day gains of +349%! At one point KDRH was literally up +1,588%!
If you missed out on my last incredible trading opportunity then don’t worry because today’s new pick has serious short-term upside potential right now!
This is why I want you to get BPSR front and center on your trading screen right now for Thursday’s 1/12/17 trading session! Hurry up and start your research immediately.
BPSR is a 16 cent trade opportunity that could produce real double to triple digit gains. Why Wait?
BPSR could produce real double to triple digit gains based on the fact that it has a 52-week high of $1.25.
This gives BPSR real upside potential of +671%. BPSR definitely has plenty of room to run from here!
In fact; Even if BPSR just ran back up to $0.22 (it hit $0.22 at the end of December) traders would be looking at profits of up to +35%!
Miss the +349% winner from Tuesday’s 1/10/17 trading session? Then don’t miss (BPSR) and get ready.
BPSR is a solid biotech play that is fully loaded with strong gain potential.
Volume is starting to pick up again and the last time shares of BPSR started to see an increase in investor interest it ran from a low of $0.06 to a high of $0.22! That’s a mega +266% move!
The 14-day RSI also just crossed over 50 and into bullish territory signaling a near- breakout.
Are you seeing what I’m seeing? The chart is a thing of pure beauty! And now that investor interest is starting to rapidly increase we could have another major breakout about to take place like back in December.
Remember to always do your own research and due diligence and that I’m not a licensed financial advisor.
On December 13th, BPSR opened at a low of $0.06 and hit a high of $0.22 per share on December 22nd.
Did you read what I just wrote? Traders got a REAL CHANCE to capture REAL PROFITS of up to +266% over 8 trading sessions!
And oh yeah, I forgot to mention that…
… StockTA has given (BPSR) an OVERALL BULLISH Rating and BULLISH Rating for the short-term!
Exponential Moving Average (EMA) Analysis: BULLISH
Moving Average Convergence Divergence (MACD) Analysis: VERY BULLISH
Fibonacci Analysis: BULLISH
High Analysis: VERY BULLISH
Trend Analysis: BULLISH
Stochastic Analysis: VERY BULLISH
Recent CandleStick Analysis: BULLISH
BPSR Company Profile
Biotech Products Services & Research Inc. focuses on a lifestyle of health and wellness. Their vision is to be a vertically integrated company, which primarily provides a patient referral service for integrative cellular therapies. Biotech also markets cellular products to doctors and hospitals.
Biotech aims to be the leader in the industry of innovative cell-based therapeutic with their unique strategy, which will guide a future of customized disease management. Biotech also sells women’s fashion products through its Ethan New York subsidiary as part of our vertically integrated health and wellness vision.
Based out of Florida, they specialize in the discovery, development and dispatch of cellular management protocols and cellular products for disease management including inflammatory and Anti-aging and regeneration conditions for patients all over the world. They specialize in anti-aging and natural regenerative medicine.
They are a publicly traded biotech company, focusing their efforts on cellular products and allografts. A dedication to innovation makes them trailblazers in the use of cellular management product for diseases, inflammations and anti-aging.
They focus on both beauty from within and beauty from without. With this in mind they opened their first ladies retail boutique called Ethan New York.
BPSR also provides cellular products to doctors and hospitals worldwide, and is planning to patent several products for anti-aging, regeneration and cosmetics.
BPSR sells cellular based products made for medical, anti-aging and cosmetic purposes. They have a patient referral network, which allows patients to be treated for various medical conditions within their own network of doctors. Cellular disease managements, are provided to individual patients by their physician, where as many other products are sold all over the world in clinics, hospitals, spas and retail stores.
They aim to be the leader in the industry of innovative cell-based therapeutics with their platform, which will guide a future of customized therapies and medicine that change the outcomes of disease and the face of medicine as we know it.
Cellular management is among the most auspicious medical technologies of our era. Cell management supports and repairs damaged tissue and organs, and can be used to renew and even restore the haemopoietic (blood and lymph) system of cancer patients.
BPSR is a rapidly expanding company focusing on the development and clinical application of inventive cell-based therapeutics in the US.
BPSR has capable and highly committed specialists working in the science and medical fields, governed by the reverance human life and health.
Cell therapy product contract manufacturer dedicated to maintaining potent expertise and knowledge.
Stem cells are cells that are capable of both regeneration and differentiation, undergoing asymmetric division, where one of the daughter cells maintains the properties of the original cell and the other begins to become a more specialized cell type.
Because of this, they are key to normal human development and a potential source of new cells that can repair diseased or damaged tissue.
Their Mission
BPSR is dedicated to the study and development of lifestyle changes and management services that might help to treat numerous degenerative diseases, as well as preventative and Anti-Aging therapies.
Their customers are people who are looking to better their lives with more than what the standard medical industry has to offer. In accordance with their commitment to safety, they provide education along side the science needed so they can make the best decision regarding cellular therapies.
They are wholly committed to aiding those with severe diseases and conditions learn more about patient-specific, innovative cellular management. They are formulating skin and hair care product lines, backed by science, that they believe they may help to improve skin and hair to give people their ”Best Chance Yet” to look and feel better.
BPSR is a 16 cent trade opportunity that could produce real double to triple digit gains. Why Wait?
BPSR could produce real double to triple digit gains based on the fact that it has a 52-week high of $1.25.
This gives BPSR real upside potential of +671%. BPSR definitely has plenty of room to run from here!
In fact; Even if BPSR just ran back up to $0.22 (it hit $0.22 at the end of December) traders would be looking at profits of up to +35%!
Miss the +349% winner from Tuesday’s 1/10/17 trading session? Then don’t miss (BPSR) and get ready.
______________
If you missed out on my latest +349% winner from Tuesday’s 1/10/17 trading session then hurry up and get BPSR front and center on your trading screen!
Start your research and due diligence on BPSR now.
P.S. – My track record has been seriously awesome! Just take a look at some of my biggest verified winning trade ideas below:
My Top Trade Alerts
9/1/16 – (SMCE) Ran From .0248 to .035 = +41pct
9/6/16 – (DCLT) Ran From .0028 to .013 = +364pct
9/13/16 – (FLCR) Ran From .0016 to .0065 = +306pct
9/20/16 – (QPRC) Ran From .0022 to .006 = +172pct
9/23/16 – (BLGA) Ran From .0079 to .0155 = +96pct
9/27/16 – (PSNX) Ran From .0089 to .014 = +57pct
9/30/16 – (CORMF) Ran From .4601 to .558 = +21pct
10/04/16 – (AOXY) Ran From .05 to .11 = +120pct
10/07/16 – (ELRN) Ran From .01 to .0425 = +325pct
10/10/16 – (UNDT) Ran From .02 to .145 = +625pct
10/13/16 – (PLLX) Ran From .0388 to .1529 = +294pct
10/18/16 – (ABBY) Ran From .004 to .01534 = +283pct
10/21/16 – (EMAV) Ran From .005 to .0606 = +1112pct
10/25/16 – (ACNV) Ran From .007 to .018 = +157pct
10/27/16 – (NSEH) Ran From .012 to .0299 = +149pct
11/04/16 – (JFIL) Ran From .014 to .0375 = +167pct
11/09/16 – (CGYG) Ran From .03 to .06 = +100pct
11/18/16 – (DTST) Ran From .05995 to .13 = +116pct
11/28/16 – (IEGH) Ran From 5.00 to 5.95 = +19pct
12/02/16 – (KSIX) Ran From .36 to .48 = +33pct
12/06/16 – (STLT) Ran From .58 to .80 = +37pct
12/21/16 – (EMAV) Ran From .0065 to .024 = +269pct
12/22/16 – (ECEZ) Ran From .007 to .0101 = +44pct
12/27/16 – (AEXE) Ran From .0145 to .027 = +86pct
1/10/17 – (KDRH) Ran From .0169 to .076 = +349pct
These Percentage Runs Are Based From The Open To HOD
Make sure to always do your own research and due diligence on any day and swing trade alert I bring to your attention. I am not a licensed financial advisor.
Also always remember that every single alert I send is very volatile and risky. Any one of them could turn into a big loser. In my personal opinion, no matter how much potential any company has, 99pct of the time all that matters is how it trades. If a company doesn’t trade well, nothing else matters. Don’t believe the hype. Be sure to use a tight stop, book gains quickly on these volatile trades, never let any one trade move too far against you, watch out for gaps, make sure the company is trading in a healthy way before you enter, and monitor it closely to make sure momentum is positive. It’s always safest to book gains quickly, even on alerts with long-term potential. (Amateur biased unlicensed opinions)
Pursuant to an agreement between SmallCapFirm and Solas Marketing Firm LLC (a non affiliated 3rd party), SmallCapFirm has been hired for a period beginning on 1/11/17 and ending on 1/12/17 to publicly disseminate information about (BPSR) via Website, Email and SMS. We have been paid six thousand USD via bank wire transfer. We own zero shares of (BPSR).
SmallCapFirm’s full disclaimer is to be read and fully understood before using SmallCapFirm’s website, or joining SmallCapFirm’s email or text list. By viewing SmallCapFirm’s website and/or reading SmallCapFirm’s email or text newsletter you are agreeing to SmallCapFirm’s full disclaimer which can be read at:
